RxDoctor Payments Data

Michael Sinfuego

Family · Valencia, CANPI 1174235451

Payments from drug & device makers

$859in general payments, 2019–2025

Across 41 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$331
  • AstraZeneca$189
  • Calliditas Therapeutics US Inc.$53
  • Novo Nordisk$47
  • Merck$30
  • Ascendis Pharma Endocrinology Inc$28
  • plus $181 from 8 others

What the payments were for

  • Food & beverage$859100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$859 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$232,136
Medicare patients
458
Services billed
2,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate16$73,639
OzempicSemaglutide29$36,460
FarxigaDapagliflozin Propanediol15$21,355
JardianceEmpagliflozin15$15,415
MounjaroTirzepatide12$12,295
LinzessLinaclotide13$6,925
Icosapent Ethyl14$3,380
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen50$905
Albuterol Sulfate HfaAlbuterol Sulfate18$621
Metformin Hcl40$403
Atorvastatin Calcium50$381
Metoprolol Succinate31$323
Famotidine11$287
Gabapentin35$269
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide15$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$47$36,46029 claims
AstraZenecaFarxiga$189$21,35515 claims
Lilly USA, LLCMounjaro$24$12,29512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,634 family providers in California.

Other family in Valencia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →